Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zolmitriptan (Zomig).

Alan M Rapoport1, Marcelo E Bigal, Stewart J Tepper

  • 1College of Physicians and Surgeons, Columbia University, New York, NY, USA. alanrapoport@nech.net

Expert Review of Neurotherapeutics
|April 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review.

Headache·2026
Same author

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon.

Headache·2025
Same author

Optimising combined treatment for migraine and temporomandibular disorders (TMDs).

Cephalalgia : an international journal of headache·2025
Same author

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.

CNS drugs·2024
Same author

Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints.

Expert review of neurotherapeutics·2024
Same author

Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older.

Expert review of medical devices·2023

Zolmitriptan (Zomig) offers various formulations for migraine relief, including tablets, orally disintegrating tablets, and nasal spray. Different zolmitriptan options provide clinical advantages for migraineurs, with higher doses showing early benefits.

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Therapeutics

Background:

  • The development of triptans for migraine treatment is ongoing, with new agents offering distinct pharmacokinetic profiles.
  • Zolmitriptan (Zomig) presents multiple delivery options to address diverse patient needs and migraine characteristics.

Purpose of the Study:

  • To review the pharmacokinetic properties and clinical advantages of different zolmitriptan formulations.
  • To highlight the selection of optimal zolmitriptan delivery routes for effective migraine management.

Main Methods:

  • Review of pharmacokinetic data for zolmitriptan formulations.
  • Analysis of clinical efficacy across different migraine subtypes and delivery routes.
  • Comparison of 2.5-mg versus 5-mg zolmitriptan doses.

Related Experiment Videos

Main Results:

  • Conventional zolmitriptan tablets are effective for various migraine subtypes.
  • Orally disintegrating tablets and nasal spray offer advantages for early treatment and patients experiencing nausea.
  • The 5-mg dose of zolmitriptan demonstrates enhanced benefits at early time points compared to the 2.5-mg dose.

Conclusions:

  • Zolmitriptan provides flexible treatment options for migraine sufferers.
  • Physicians can tailor zolmitriptan's route of administration and dosage to optimize headache cessation, reduce disability, and restore patient function.